ST. LOUIS & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Monsanto Company (NYSE: MON) and Second Genome, Inc. have announced a research agreement to accelerate the discovery of new microbiome-based solutions to help farmers better manage environmental challenges on their farms. The collaboration will leverage Monsanto’s extensive genomic databases with Second Genome’s expertise in analyzing microbial function through big data metagenomics, protein discovery, machine learning, and predictive analytics. This research will immediately expand the sourcing and diversity of novel proteins for the development of next-generation insect-control solutions. “Data science holds tremendous promise in unlocking new discoveries across our entire research and development pipeline,” said Tom Adams, Ph.D., biotechnology lead for Monsanto. “This collaboration highlights how advances in biology and data science are converging to create opportunities for agriculture to identify new solutions to age-old problems. Through Second Genome’s analytics, we aim to better predict the effectiveness of new applications across our research and crop portfolios.” Under the agreement, Second Genome will apply its novel bioinformatics platform to predict and analyze the efficacy of beneficial proteins from the microbiome for agricultural use. The companies anticipate that the research will increase the discovery of proteins that could provide an insect-control benefit in agriculture. The multi-year agreement provides Monsanto with the option to pursue commercial opportunities resulting from insect-control research in agriculture, and Second Genome retains the right to apply discoveries in healthcare and other industries. Additional terms of the agreement were not disclosed. “Similar to its role in human health, microbial function has a significant influence in agricultural applications and new research in microbiome science is likely to unlock new solutions for the agriculture industry,” said Glenn Nedwin, Ph.D., CEO and President at Second Genome. “This collaboration allows us to apply our broad microbiome technology platform with Monsanto’s vast microbial function data to develop new solutions that will contribute to the prosperity of growers in the future. At the same time, we can continue to focus our programs on areas of human health, where our team has demonstrated an ability to discover molecules of interest for major unmet medical needs.” About Second Genome Second Genome is a privately-held company based in South San Francisco, CA, that is leveraging expertise in microbiome science to discover and develop novel healthcare products, including therapeutic candidates for inflammatory bowel and metabolic diseases. Second Genome’s microbiome technology platform has broad applications in human and animal healthcare, nutrition, agriculture, the environment and industrial applications. Please visit www.secondgenome.com for more information. About Monsanto Company Monsanto is committed to bringing a broad range of solutions to help nourish our growing world. We produce seeds for fruits, vegetables and key crops – such as corn, soybeans, and cotton – that help farmers have better harvests while using water and other important resources more efficiently. We work to find sustainable solutions for soil health, help farmers use data to improve farming practices and conserve natural resources, and provide crop protection products to minimize damage from pests and disease. Through programs and partnerships, we collaborate with farmers, researchers, nonprofit organizations, universities and others to help tackle some of the world’s biggest challenges. To learn more about Monsanto, our commitments and our more than 20,000 dedicated employees, please visit: discover.monsanto.com and monsanto.com. Follow our business on Twitter® at twitter.com/MonsantoCo, on the company blog, Beyond the Rows® at monsantoblog.com or subscribe to our News Release RSS Feed. Cautionary Statements Regarding Forward-Looking Information: Certain statements contained in this release are “forward-looking statements,” such as statements concerning the company’s anticipated financial results, current and future product performance, regulatory approvals, business and financial plans and other non-historical facts. These statements are based on current expectations and currently available information. However, since these statements are based on factors that involve risks and uncertainties, the company’s actual performance and results may differ materially from those described or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, among others: continued competition in seeds, traits and agricultural chemicals; the company’s exposure to various contingencies, including those related to intellectual property protection, regulatory compliance and the speed with which approvals are received, and public understanding and acceptance of our biotechnology and other agricultural products; the success of the company’s research and development activities; the outcomes of major lawsuits; developments related to foreign currencies and economies; the impact of exploring, responding to, entering into or consummating potential acquisitions or other transactions and proposals; fluctuations in commodity prices; compliance with regulations affecting our manufacturing; the accuracy of the company’s estimates related to distribution inventory levels; the recent increases in and expected higher levels of indebtedness; the company’s ability to fund its short-term financing needs and to obtain payment for the products that it sells; the effect of weather conditions, natural disasters, accidents, and security breaches, including cybersecurity incidents, on the agriculture business or the company’s facilities; and other risks and factors detailed in the company’s most recent periodic report to the SEC. Undue reliance should not be placed on these forward-looking statements, which are current only as of the date of this release. The company disclaims any current intention or obligation to update any forward-looking statements or any of the factors that may affect actual results. Multimedia Files: Download All Files